Pharmaceutical Contract Sales Force
i am working for a global market research firm based out of bangalore, india. I am currently working on a project on contracted sales force (csf) specific for pharmaceuticals sector. I am trying to understand the csf market and have some specific queries on the same. My queries are mentioned below:
1. How is the pharma sales and marketing landscape changing and how does cso help in the marketing efforts to the pharma companies?
2. What strategies pharma companies are adopting for outsourcing sales and marketing activities?
3. What is the market dynamics of contracted sales force in the next 2–3 years?
4. What are the contractual aspects of the contracted sales force?
5. What are the procurement best practices followed in the pharma industry while engaging with a cso?
6. What can be a typical cost structure for a contracted sales force supplier?
If you could share some information on the same, it would be of great help with my report.+10 Other Responses
chief scientific officer
a commercialization-stage start-up biopharmaceutical company developing innovation workstation to improve efficacy and cost-effectively in the drug development and manufacture. The corporate office is located in san francisco bay, ca and setting up an oversea corporation entity, this pre-ipo company is entrepreneurial and fast-moving in nature and desires additional team members with similar qualities.
o a key member of the senior executive team, engaged in defining the overall scientific strategy and direction of the organization.
O lead and active engagement in business opportunities including presenting business and scientific capabilities to partners and other key current and potential stakeholders
o scientific oversight, expertise and leadership, include the development and implementation of innovative technology, including collaboration with strategic business partner
o build and leverage cross functional collaborative relationships to achieve shared company goals
o participate in financing and business development activities providing a business perspective and scientific review for internal decision making and to external investors and analysts.
O prepare for global scientific strategy, planning and appropriate budgets for resource requirements and allocation
o promote collaboration to both internal and external team member
language: english and chinese. Please note: chinese language is a requirement because this position may require part-time work in china facility.
o an phd with 10 to 15 years of experience and held senior positions within biopharmaceutical company
o focused hematology/oncology with experience in working with the scientific team, and investors
o determined executive with strong interpersonal skills, comfortably integrating into a senior-level, high profile role and able to achieve results.
O demonstrated strategic and innovative thinker with proven ability to communicate a vision and drive results
o ability to proactively identify and solve problems and execute on initiatives
o demonstrated ability to assess business needs, design and implement programs and evaluate results
the chief scientific officer will be a determined executive with strong interpersonal skills with business partners and investors, comfortably integrating into a senior-level, high profile role and able to achieve results. Must be hands-on and detail-oriented, while still being able to see the big picture. A self-motivated, approachable, articulate team player, the chief scientific officer, will have the highest level of integrity and core value system that are consistent with the organization as a whole.
commensurate upon experience. Pre-ipo company, 3-6 months deferred executive pay, equity position. Willingness to become a partner in a fast-growing, entrepreneurial company is preferred+10 Other Responses
We are currently looking to understand the pharma distribution strategy adopted by orphan drug (drugs to treat rare disease) manufacturers in australia. We know that australian market is dominated by three major cso distributors (api, sigma and x
b) and major generic drug manufacturers prefer to engage with these 3 wholesalers as they have the maximum distribution point of sales and are required to supply drugs listed in pbs.
1. So based on this, would like to know if orphan drug manufacturers also use these wholesalers or do they prefer direct distribution using dhl or world couriers, or any other strategy?
2. Would like to get some case specific to orphan drug distribution in australia.
Thank you and looking forward.
+10 Other Responses